SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following a massive, unsolicited $56 billion bid to acquire eBay, a move that has ignited intense debate over potential stock dilution versus the strategic ambition to build an e-commerce rival to Amazon. The community remains deeply polarized, with bulls viewing the play as a bold, long-term transformational move, while vocal bears and skeptics are heavily criticizing the CEO's confrontational media presence and the logistical hurdles of the proposed financing.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing intense investor interest driven by a massive short squeeze setup, characterized by high borrowing costs and low share availability. The community is focused on the upcoming earnings report as a major catalyst for momentum, with many bulls actively discouraging selling and urging a long-term hold to maximize pressure on short sellers.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadu Quantum Technologies is experiencing extreme volatility driven by a prospectus filing that registers a large volume of existing Class B shares for potential resale, which the community is debating as either a standard liquidity event or a sign of an impending supply overhang. Investors are actively discussing the technical merits of the company's photonic quantum approach, while many express mixed sentiment over the stock's speculative nature and the rapid price fluctuations following the registration news.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending as investors aggressively buy into a structural memory supercycle, with community members highlighting that AI infrastructure demand for DRAM and HBM is decoupling the stock from traditional cyclical patterns. Bullish sentiment remains dominant as market participants point to supply shortages and major hyperscale partnerships as the primary drivers, with many actively discussing the potential for a massive rerating as the stock approaches new highs.

Elong Power Holding Ltd. engages in the research and development, manufacturing, sales and service of high-power lithium-ion batteries for electric vehicles and construction machinery, as well as large-capacity, long-cycle lithium-ion batteries for energy storage systems. The company was founded on August 18, 2023 and is headquartered in Ganzhou, China.

Elong Power Holding Ltd. - Ordinary Shares - Class A

Elong Power Holding Limited

Elong Power Holding Limited (ELPW) is experiencing high-volume volatility and active short-squeeze speculation, with the community closely tracking the ticker alongside other low-float, China-based small caps. Retail traders are intensely focused on key price levels and resistance breakouts while debating the sustainability of the move versus potential downside risk.

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Cns Pharmaceuticals is experiencing intense volatility and volume as investors react to a private placement financing announcement, fueling intense community debates about potential squeezes versus long-term dilution concerns. Retail traders are closely monitoring the stock's tight float and rapid price swings, with active discussions centered on technical breakout levels and the company's shifting strategic focus.

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.

Clene Inc

Clene Inc. is currently a focal point for investors as the community anticipates critical upcoming data regarding biomarker analysis and potential FDA accelerated approval pathways for its ALS candidate, CNM-Au8. Discussion is heavily focused on the company's regulatory roadmap, the impact of recent insider selling, and the broader context of how emerging biomarker evidence could influence the stock's long-term valuation.

High-Trend International Group is a holding company. It engages in shipping decarbonization and carbon asset management platforms. The company was founded in 2021 and is headquartered in Singapore.

High-Trend International Group. - Ordinary Shares - Class A

HTCO is experiencing significant volatility driven by heavy short interest and a low-float structure, with community discussions largely centered on aggressive short squeeze potential and speculative trading dynamics. Investors are debating the sustainability of the price action, frequently drawing parallels to past momentum plays while others warn of the risks associated with rapid, news-sparse price swings.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending following an unsolicited takeover proposal from GameStop, which has fueled intense community debate over the feasibility of the deal and the potential for a massive acquisition strategy. Market participants are actively scrutinizing the financing requirements and the viability of a cash-and-stock offer that significantly exceeds GameStop's current market valuation.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending as investors rally behind the upcoming April 30 PDUFA date for the label expansion of Auvelity into Alzheimer's disease agitation. The community is heavily focused on the stock's multi-year growth trajectory, institutional accumulation, and the potential for Auvelity to become a dominant CNS blockbuster, with many discussing its prospects as a prime acquisition target for big pharma.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nuwellis Names Carisa Schultz CFO

(RTTNews) - Nuwellis, Inc. (NUWE), a medical technology company, on Friday announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2...

<ul class="summary-bullets"><li>Nuwellis did not disclose the value of the deal that is aimed at expanding the company’s portfolio into real-time renal diagnostics.</li><li>The company said that the transaction is expected to close upon the completion of customary closing conditions.</li><li>The Minneapolis-based company also announced a $5 million private placement and warrant inducement transaction priced at-the-market.</li></ul> Shares of Nuwellis Inc. (NUWE) slumped over 16% after-hours on Thursday after the company said that it has inked an agreement to acquire Israeli medical technology company Rendiatech.Nuwellis did not disclose the value of the deal, which is aimed at expanding the company’s portfolio into real-time renal diagnostics beyond therapeutic fluid management. Rendiatech is focused on automated kidney function monitoring.The company’s current portfolio includes commercially available and development-stage technologies addressing complex cardiorenal conditions. &nbsp;<h2 class="st-heading-2">Upsides Of The Transaction</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229142/26106/en/Nuwellis-Enters-into-Definitive-Agreement-to-Acquire-Rendiatech-Advancing-Its-Cardiorenal-Portfolio-Strategy.html">said </a>that the transaction is expected to close upon the completion of customary closing conditions.Upon closing, Nuwellis will gain access to Rendiatech’s Clarity technology, allowing for expansion into advanced urine-based analytics and broader kidney function assessment, the company said, adding that the establishment of new sales channels is not expected to be needed to develop Rendiatech’s technology.“By entering into this transaction, we are positioning the company to extend our capabilities beyond therapeutic fluid removal and into real-time renal monitoring, which we believe is a natural and complementary evolution of our portfolio,” CEO John Erb said.Separately, the Minneapolis-based company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/29/3229143/26106/en/Nuwellis-Announces-5-Million-Private-Placement-and-Warrant-Inducement-Transaction-Priced-At-The-Market.html">announced</a> a $5 million private placement and warrant inducement transaction priced at-the-market. The transaction is expected to close on or about Jan. 30.The company did not detail the purposes for which the proceeds will be used. &nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around NUWE stock stayed at ‘extremely bullish’ territory while message volume stayed at ‘extremely high’ levels.A Stocktwits user said that they are bullish on the acquisition until proven otherwise.<stembedurl>https://www.stocktwits.com/Nuckle_Head/message/643368696</stembedurl><a href="https://stocktwits.com/symbol/NUWE">NUWE stock</a> has dropped over 90% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/spacex-reportedly-considering-merger-with-xai-ahead-of-planned-ipo/cmyilBJR41B">Elon Musk’s SpaceX Reportedly Considering Merger With xAI Ahead Of Planned IPO</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Shares of InMode have fallen nearly 12% over the past 12 months. 

Nuwellis Stock Slips Over 26% After Hours On New Acquisition, $5M Placement Announcement

The company did not disclose the value of the acquisition, which is aimed at expanding the company’s portfolio into real-time renal diagnostics.

Equity

Nuwellis, Inc. Profit Declines In Q3

(RTTNews) - Nuwellis, Inc. (NUWE) announced earnings for third quarter that Dropped, from last year...

Nuwellis shares rose in after-hours trading after the company said it was granted a new U.S. Patent for innovations in blood filtering machine design and methods that improve fluid management accuracy during ultrafiltration therapy.At the close on Tuesday, <a href="https://stocktwits.com/symbol/NUWE">Nuwellis shares</a> dropped 11.7% to $6.9, but surged 31.3% to $9.05 in after-hours trading following news of the patent grant.The patent, titled “Extracorporeal Blood Filtering Machine and Methods”, addresses a critical source of error in continuous renal replacement therapy (CRRT) by factoring in actual fluid density, rather than assuming a standard value.&nbsp;Most current systems use 1 g/mL as&nbsp;the&nbsp;default, which can lead to miscalculations in fluid balance when actual densities differ.&nbsp;The new approach allows machines to adjust calculations based on input, measurement, or derived values, improving volumetric flow tracking and patient care.The company,&nbsp;based in Minneapolis with operations in Ireland,&nbsp;markets the Aquadex SmartFlow system for ultrafiltration and is&nbsp;The patent comes on the heels of two other major corporate developments in recent months.&nbsp;In June, Nuwellis raised $4.3 million through an underwritten public offering that included common stock and warrants. The company said the proceeds would go toward working capital, general corporate purposes, and potential acquisitions.In May, Nuwellis finalized a manufacturing agreement with KDI Precision Manufacturing, transferring assembly responsibilities for its Aquadex SmartFlow console and related products.&nbsp;The partnership&nbsp;aims to expand manufacturing capacity and enhance operational efficiency, with KDI also hiring current Nuwellis assembly employees to ensure a seamless transition.On Stocktwits, retail sentiment for Nuwellis was ‘extremely bullish’ by late Tuesday, improving from the ‘bullish’ mood a day ago, amid ‘extremely high’ message volume.One user said that a back-to-back spike within 24 hours typically signals that a larger move is underway.&nbsp;<stembedurl>https://stocktwits.com/Enjoiskating1216/message/621091545</stembedurl>Another expressed confidence in a major upside, suggesting the stock could revisit the $50 mark.<stembedurl>https://stocktwits.com/BestNwest/message/621099818</stembedurl>Nuwellis’ stock has declined 86.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nuwellis (NUWE) was granted a new U.S. Patent for innovations in blood filtering machine design. (Photo credit: Getty Images)

Nuwellis Stock Rises After Hours Following Patent Win For Blood Filtering System — Retail Mood Turns Buoyant

The patent for its blood filtering technology aims to improve fluid balance accuracy in CRRT by accounting for actual fluid density instead of relying on standard assumptions.

Nuwellis, Inc. (NUWE) Reports Q1 Loss, Lags Revenue Estimates

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon following its announcement that the Centers for Medicare and Medicaid Services (CMS) will significantly hike the reimbursement levels for its ultrafiltration therapy, lifting retail sentiment. Effective January 1, 2025, the reimbursement payment rate for the Minneapolis-based company’s Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase from $413 to $1,639 per day, a major step for the company’s outpatient therapy.&nbsp; Stocktwits users celebrated the move, suggesting the stock should go much higher following the news.&nbsp; &nbsp;<stembedurl>https://stocktwits.com/xpb199/message/591140624</stembedurl><stembedurl>https://stocktwits.com/Rampageusa/message/591116254</stembedurl> &nbsp;"This change underscores the clinical importance and cost-effectiveness of our ultrafiltration technology and will expand patient access to this life-saving therapy,” Nestor Jaramillo, President and CEO of Nuwellis, said in a statement. “It is well understood that providing care in an outpatient setting can be a better means to manage disease and prevent costly emergency hospitalizations.”&nbsp; The move will help expand the therapy’s reach to more patients on the sub-acute or chronic disease management program.Nuvellis plans to report its <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.marketwatch.com/story/nuwellis-shares-surge-following-preliminary-3q-results-c5fa917d">third-quarter</a> results and host its earnings conference call on November 11. The company said recently it is expecting to report revenue of $2.4 million, in line with the year-ago period.Nuwellis shares rallied over 106% today, but the stock is down roughly 88% year-to-date. Still, the stock is seeing a major jump in activity among retail investors and traders, with today’s symbol page views on Stocktwits hitting more than 25x their average over their one-month average.For updates and corrections, email newsroom@stocktwits.com

Shares of medical device company Nuwellis Inc. ($NUWE) more than doubled on Monday afternoon| Image source: Pixabay

Nuwellis Stock Spikes After Reimbursement Hike: Retail’s Upbeat

Effective January 1, 2025, the payment rate for its Aquadex SmartFlow therapy, used for treating fluid overload in heart failure patients, will increase 397% from $413 to $1,639 per day.

Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.

NUWE
Nuwellis Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NUWE News

NUWENuwellis Inc